[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566835":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":29,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Phathom Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exposed Cohort",null,"Pregnant women who are exposed to vonoprazan during pregnancy.",[13],"Drug: Vonoprazan",{"label":15,"type":10,"description":16,"interventionNames":10},"Unexposed Cohort","Pregnant women who are not exposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Vonoprazan","Oral tablet.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"VOQUEZNA Pregnancy Registry","CONTACT","1-866-609-1612","DLVOQUEZNAPregnancyRegistry@ppd.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"PPD","RECRUITING","Wilmington","North Carolina","28401","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-77.94604,34.23556,{"lat":42,"lon":41},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100566835","a-study-of-the-safety-of-vonoprazan-exposure-in-pregnant-women-and-their-offspring-100566835",false,"NCT06660342","A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Inclusion Criteria:\n\n* Women 15 to 50 years of age.\n* Currently or recently pregnant.\n* Consent to participate.\n* Authorization for her health care provider(s) (HCP\\[s\\]) to provide data to the registry.\n* Exposed cohort: Exposure to at least one dose of vonoprazan during pregnancy.\n* Unexposed cohort: Unexposed to vonoprazan and diagnosis of any condition for which vonoprazan may be prescribed.\n\nExclusion Criteria:\n\n* Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).\n* Exposure to known tetratogens and\u002For investigational medications during pregnancy.\n* Lost to follow-up.","FEMALE","15 Years","50 Years",{"count":57,"type":58},728,"ESTIMATED","12 Months","OBSERVATIONAL","The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.",[63,64,65,66],"Erosive Esophagitis","Heartburn","Symptomatic Non-erosive Gastroesophageal Reflux Disease","Helicobacter Pylori Infection",[63,64,65,66,68,69,70],"Pregnant Women","Fetal","Infant","2025-05-21",{"date":73,"type":74},"2025-05-22","ACTUAL",{"date":76,"type":74},"2025-05-15",{"date":78,"type":58},"2034-09",{"name":5,"class":6},1]